Kornimate/medical-research-clean huggingface dataset:
anesthesia quality improvement and patients with planned icu admission

Conditions: Anesthesia; Extubation; Intensive Care Unit; Postoperative Complications

Summary: intensive care unit (icu) is an important part of perioperative management for high-risk patients but is associated with higher medical costs. improper icu admission may produce overtreatment without beneficial effects. in clinical practice, delayed recovery after general anesthesia is a common indication for icu admission after surgery. the concept of enhanced recovery after surgery recommends early extubation. the investigators suppose that, for patients with planned icu admission after elective surgery, implementing anesthesia quality improvement including extubation in the operating room will reduce the rate of icu admission after surgery without increasing complications.

intensive care unit (icu) is an important part of perioperative management for high-risk patients but is associated with higher medical costs. improper icu admission may produce overtreatment without beneficial effects. studies found that immediate icu admission after surgery did not reduce the perioperative mortality. some authors suggested that the indication of icu admission should be the occurrence of postoperative complications, which will reasonably reduce the use of medical resources. in clinical practice, delayed recovery after general anesthesia is a common indication for icu admission after surgery. old age, high asa grade, respiratory complications, long duration surgery, large-volume fluid infusion, and use of vasopressors were main factors associated with delayed recovery. the concept of enhanced recovery after surgery recommends early extubation after surgery. studies showed that, for patients after organ transplantation, immediate extubation in the operating room can shorten hospital stay and reduce medical costs, without increasing mortality. the investigators suppose that, for patients with planned icu admission after elective surgery, implementing anesthesia quality improvement including extubation in the operating room will reduce the rate of icu admission after surgery without increasing postoperative complications.

Eligibility criteria:
inclusion criteria: * age ≥18 years. * scheduled to undergo elective surgery. * planned icu admission after surgery. exclusion criteria: * refused to participate in the study. * icu admission before surgery. * unexpected icu admission. * other conditions that are considered unsuitable for study participation.

Keywords: anesthesia management early extubation intensive care unit admission postoperative complications
community-based precise management for patients with coronary artery disease

Conditions: Coronary Artery Disease

Summary: the community-based precise management for patients with coronary artery disease study is a prospective, cluster-randomized, open-labeled trial. the purpose of this trial is to test whether a community-based precise management and rehabilitation model under the hierarchical medical system could help improve the cardiovascular risk factors control in patients with coronary artery disease. additionally, the trial will also evaluate the impact of the model on major cardiovascular adverse events in patients with coronary artery disease.


Eligibility criteria:
inclusion criteria: * patients with prior myocardial infarction * or receiving percutaneous coronary intervention or coronary artery bypass graft; * or coronary artery stenosis≥50% defined by coronary angiography or coronary ct angiography exclusion criteria: * refuse to sign the written informed consent; * patients without the ability to take care of themselves; * mental disorders; * alcoholics or drug addicts; * cannot be followed up for any reasons; * life expectancy\<1 year due to non-cardiovascular reasons.

Keywords: coronary artery disease risk factor control community-based management secondary prevention
real-life data of cardiovascular events occuring during degarelix therapy for prostate cancer

Conditions: Advanced Hormone Sensitive Prostate Cancer

Summary: patients with prostate cancer and a history of cardiovascular disease treated with degarelix for their prostate cancer, will be followed for a period of one year. in this real-life, non-interventional trial, any cardiovascular events occurring during degarelix therapy will be documented.


Eligibility criteria:
inclusion criteria: * patients with prostate cancer and a history of cardiovascular disease, prescribed degarelix for the treatment of their prostate cancer exclusion criteria: * patients who have received a form of androgen deprivation therapy for their prostate cancer, during the 12 months preceding this study are excluded * planned intermittent or short-term (\< 12 months) degarelix treatment * planned addition of, or switch to another form of androgen deprivation therapy during the study
oral green tea extract for small cell lung cancer

Conditions: Small Cell Lung Carcinoma

Summary: the purpose of this study is to determine whether green tea extract is safe for extensive-stage small lung cancer who achieved objective tumor response after first-line therapy.

small-cell lung cancer accounts for 13 to 15% of all lung cancer and more than 60 to 70% of patients present with extensive disease (ed). although etoposide plus cisplatin (ep) regimen has been the mainstay of ed-sclc treatment, median overall survival is about 9 months, with 5 to 10% surviving two years and only 1% of patients achieving a long-term disease-free survival. to improve this outcome further, various attempts have been made, which included dose intensification with stem cell supports, maintenance therapy, and also searches for a better chemotherapy regimen. significant anticarcinogenic effects of green tea extract on various organs, such as skin, stomach, duodenum, colon, liver, pancreas, and lung in rodent models have been confirmed. recent scientific investigations have identified the active chemical compounds in green tea designated tea polyphenols or catechins. epigallocatechin-3-gallate (egcg) is the major catechin in tea.an investigation about the effects of egcg on human sclc cells revealed that egcg had similar anti-tumor effects on drug-sensitive (h69) and drug-resistant (h69vp) sclc cells. thus, the investigators conduct this phase i trial, the objectives of this trial were to study the side effects and best dose of of egcg in treating patients with small-cell lung cancer who achieved objective tumor response after first-line therapy.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of small cell lung cancer * extensive-stage disease * eastern cooperative oncology group performance status (ps) of 0 to 2 * age18 years old * adequate bone marrow reserves: neutrophil (anc) count ≥ 1500 /mm\^3, platelet count ≥ 100,000 /mm\^3, hemoglobin ≥ 9 g/dl * adequate renal function: serum creatinine ≤ 1.5 mg/dl and/or calculated creatinine clearance ≥ 60 ml/min * adequate hepatic function: bilirubin level ≤ 1.5 x uln, asat \& alst ≤ 1.5 x uln * signed written informed consent prior to study entry * according to response evaluation criteria in solid tumors(recist), patients didn't progress after first-line chemotherapy exclusion criteria: * any condition that would hamper informed consent or ability to comply with the study protocol * participation in another research study in the last three months * known malignancy at any site other than sclc * recent consumption of green tea (5 or more cups per day within one week of study enrollment) * pregnant and lactating women * history of allergic reactions attributed to compounds of similar chemical or biologic composition to egcg
efficacy and safety study of pitavastatin and atorvastatin in high risk hypercholesterolemic patients

Conditions: Hyperlipidemia

Summary: this is a 12-week, randomized, multicenter, double-blind, active-controlled, non-inferiority study (tatpita20101005) to compare the efficacy and safety of pitavastatin (livalo®) and atorvastatin (lipitor®) in high risk hypercholesterolemic patients.


Eligibility criteria:
inclusion criteria: * patient aged ≥ 20 years old and \< 75 years old. * patient who was eligible and able to participate in the study and accepts to enter the study by signing written informed consent. * patient with fasting ldl-c \> 100 mg/dl. the concentration of ldl-c is obtained from laboratory examination. * patient with at least one of the following description (ncep atp iii guideline). * female patient with child-bearing potential must take reliable contraception method(s) during the participation of the study. exclusion criteria: * patient who has participated in other investigational studies within 3 months. * patient took medication and natural health foods known to alter blood lipid profiles within 4 weeks. * patient is taking any medication or food that is prohibited by the study. * patient taking amiodarone will be excluded from this study (due to long half life of this medication). * patient is diagnosed with type 1 dm or has been using insulin/insulin analog medication. * patient with a history of multiple drug allergies or with a known allergy to hmg-coa reductase inhibitors. * patient with tg \> 400 mg/dl. * excessive obesity defined as bmi above 35 kg/m2. * cerebral vascular disease (including cerebrovascular hemorrhage or ischemia, transient ischemic attack) diagnosed within 3 months. * myocardial infarction, heart failure (nyha class iii or iv), gross cardiac enlargement (cardiothoracic ratio \> 0.5), significant heart block or cardiac arrhythmias within 3 months; history of uncontrolled complex ventricular arrhythmias, uncontrolled atrial fibrillation/flutter or uncontrolled supraventricular tachycardia, pacemaker or implantable cardiac device were not eligible for this study. * patient with advanced renal disorder (serum creatinine levels ≥ 2 mg/dl and bun ≥ 25 mg/dl). * patient with advanced hepatic disorder (ast or alt level ≥ 100 iu/l) * patient with ck level \> 5 × ulrr at any time point between visit 1 and visit 2. * patient with poorly controlled diabetes mellitus (hba1c \> 9.0%) or patient with severe hypertension (\> 180 mmhg for systolic or \> 120 mmhg in diastolic blood pressure). * patient with hypothyroidism, hereditary muscular disorders, family history of the above or history of drug-induced myopathy. * patient has significant alcohol consumption (\> 65 ml pure alcohol) within 48 hours before visit 2. * any major surgery within 3 months prior to visit 2. * female patient who is lactating, being pregnant or plans to become pregnant. * patient with conditions judged by the investigator as unsuitable for the study.

Keywords: hyperlipidemia pitavastatin atorvastatin
focal accumulation of iron in cerebral regions in early als (amyotrophic lateral sclerosis) patients

Conditions: ALS (Amyotrophic Lateral Sclerosis); Iron Overload

Summary: the fair-als study is to investigate the safety and efficacy of a scavenger treatment of iron deferiprone, which would reduce the brain iron to limit the development of amyotrophic lateral sclerosis. it has been shown an excess of iron in the central nervous system carrying a sporadic als patients. iron overload associated with a loss of motor neurons may explain the signs of the disease (atrophy). the investigators discuss the hypothesis that reducing excess iron, the investigators can reduce the loss of neurons and thus the progression of signs of the disease.

at the end of the study, it will propose to continue the usual quarterly patient follow up, as recommended by the french als centers. deferiprone can be administered as part of a compassionate use, for patients who want it and who do not have hypoxemia. we therefore plan a treatment period compassionate relatively short and less than 3 years.

Eligibility criteria:
inclusion criteria: * amyotrophic lateral sclerosis defined in accordance to the el escorial criteria (possible, probable or defined) * 18 to 85 years old patient, male or female * patient with social security cover exclusion criteria: * achieved respiratory defined by a fvc \<70% * evolution of more than 24 months * demented subject * severe malnutrition * patients with treatment potentially at risk of agranulocytosis and neutropenia * patients with a history of agranulocytosis or iatrogenic under haematological disease * incapable of giving consent * indication against mri * indication against lumbar puncture * patient refused lumbar puncture * hypersensitivity to iron chelators * concomitant treatment with antacids containing aluminum * presence of another serious illness to life-threatening or disabling cons to the use of the treatment mixture of oxygen and nitrous oxide equally
tonation breathing technique method to ease aromatase inhibitor-induced joint and/or muscle pain

Conditions: Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8

Summary: this clinical trial evaluates how well tonation breathing techniques (use of a breathing and tonation \[creating sounds\]) works to ease pain joint and/or muscle pain in patients with stage i-iii breast cancer and currently take an aromatase inhibitor. tonation breathing techniques may help relieve pain in patients with stage i-iii breast cancer who are receiving aromatase inhibitor.

primary objective: i. to study impact of active participation of patients in producing tones in combination with breathing technique, i.e., tonation breathing techniques (tbt) to reduce aromatase inhibitor induced musculoskeletal symptoms. outline: patients participate in tonation breathing techniques twice daily (or more if pain occurs) for 2 weeks. patients also complete questionnaire at baseline and at 2 weeks.

Eligibility criteria:
inclusion criteria: * females with stage i-iii breast cancer taking adjuvant aromatase inhibitor (ai) (either standard dose of anastrozole 1 mg daily or letrozole 2.5 mg daily or exemestane 25 mg daily) for greater than 30 days experiencing ai induced musculoskeletal pain scores of 5 or higher on a likert scale will be enrolled * subjects should have completed any planned surgery for breast cancer, chemotherapy and radiation therapy at least 30 days prior to enrollment * patients should have an eastern cooperative oncology group (ecog) performance score of 0-2 * patients should be at least 18 years old with no maximum age limit exclusion criteria: * patients should not have significant underlying pulmonary disease
supplemental selenium and vitamin e and pulmonary function

Conditions: Chronic Obstructive Pulmonary Disease; Lung Diseases; Lung Diseases, Obstructive

Summary: to test whether supplementation with selenium and/or vitamin e affects pulmonary function.

background: there is compelling evidence from observational epidemiologic studies that intakes of nutrients with antioxidant properties are associated with reduced risks of chronic obstructive disease (copd) and increased lung function. this study is ancillary to the multisite selenium and vitamin e cancer prevention trial (select), a 4-arm placebo-controlled, double-blinded randomized trial in 35,000 men testing whether daily supplementation with vitamin e (400mg alpha-tocopherol), selenium (200 micrograms selenomethionine) or both vitamin e and selenium can prevent prostate cancer. design narrative: this study is ancillary to the multisite selenium and vitamin e cancer prevention trial (select), a 4-arm placebo-controlled, double-blinded randomized trial in 35,000 men testing whether daily supplementation with vitamin e (400mg alpha-tocopherol), selenium (200 micrograms selenomethionine) or both vitamin e and selenium can prevent prostate cancer. a total of 3,000 select participants will be enrolled for this respiratory ancillary study, and data collection will be extended to include pulmonary function, respiratory disease, and respiratory symptoms. biological measures of nutrient exposure (serum vitamin e and selenium) and plasma lipids (total and high-density lipoprotein cholesterol) will be collected on all participants and oxidant burden (urinary f2-isoprostane) on a sub sample of heavy smokers and men with copd. the primary outcome will be change over about 36 months in forced expiratory volume in the first second (fev1). fev1 is a valid and reliable measure of respiratory function that strongly predicts copd and mortality. extensive data on diet and dietary supplement use are being collected by the select parent study. all specific aims examine pre-specified contrasts between the 4 arms of the select randomized trial. the underlying hypothesis is that supplements will reduce the age related decline in fev1 and thus at the 3-year follow-up fev1, which will be tested in longitudinal and cross-sectional models. a secondary aim considers whether the effect of supplementation is greater among smokers (high burden of exogenous oxidants) who, by purposive selection of the study sites, will comprise about 25% of the sample.

Eligibility criteria:
eligibility criteria: * age ≥ 55 y (≥ 50 y in african-americans) * serum prostate-specific antigen ≤ 4ng/ml * no clinical evidence of prostate cancer exclusion criteria: * off both select supplements
arrhythmias in myotonic muscular dystrophy

Conditions: Muscular Dystrophy; Arrhythmia; Sudden Cardiac Death

Summary: adult myotonic muscular dystrophy (steinert's disease) is the most common inherited neuromuscular disorder. cardiac rhythm disturbances occur frequently in this disease state and may be responsible for up to one-third of deaths. in this study, we intend to evaluate the utility of non-invasive electrocardiographic screening methods and history in predicting serious arrhythmic events.

the long term objectives of this population study is a more defined natural history, optimal diagnostic testing methodology, and methods of therapy for arrhythmias in individuals with myotonic muscular dystrophy. the goal is a more adequate definition of appropriate diagnosis and therapy for arrhythmias in order to decrease the likelihood of cardiac morbidity and mortality in this disorder. the specific aims of the study involve an initial survey of individuals with myotonic muscular dystrophy detailing multiple factors. non-invasive electrocardiographic testing will be done. using this initial data and subsequent follow-up data collected yearly the cohort of patients will be followed as to arrhythmia development over a minimum of five years and likely longer with a long-term registry and evaluation of national death records and ancestry.com. this project is unique in that it characterizes a non-neurologic abnormality associated with a neuromuscular disease, myotonic muscular dystrophy.

Eligibility criteria:
inclusion criteria: 1. age 18 and over 2. willing to sign informed consent 3. have a previous diagnosis of myotonic muscular dystrophy exclusion criteria: 1. under age 18. 2. unwilling to sign consent. 3. unwilling to commit to long-term follow-up.
efficacy of muscle energy technique alone and in combination with interferential therapy for the treatment of non-specific low back pain.

Conditions: Back Pain

Summary: single blind randomized control trail in which two groups were formed. group a was given muscle energy technique and group b was given muscle energy technique in combination with interferential therapy.

after getting the rec approval from the neurocounsel clinics, study was initiated from 21 may, 2023 to 20 september 2023. sample size was calculated by epitool which came 30. following participants were included a) both genders b) age 20-50 years and followings were excluded a) dm b) parkinson disease c) disc disorder d) msk disorder were excluded from this study. simple random sampling technique was used to randomize participants into two equal groups. group a was given met and group b was given met plus ift. 2 sessions/week for 4 \& half weeks. evaluation was done at pns \& eq-5d-5l (qol). pre and post test analysis was done by use of spss version 21 and level of significance was kept p\<0.05.

Eligibility criteria:
inclusion criteria: * both genders * age between 20-50 years old * non specific type of back pain exclusion criteria: * diabetes mellitus * parkinson disease * any other musculoskeletal disorder
effects of acutely elevated afterload on left ventricular contractility and relaxation

Conditions: Heart Failure

Summary: aim of the study is to assess the effects of abruptly increased afterload on left ventricular contractility and relaxation in patients with heart failure with preserved ejection fraction (hfpef), patients with heart failure with reduced ejection fraction (hfref), and patients without hfpef or hfref.


Eligibility criteria:
inclusion criteria: * clinical indication for left and right heart catheterization * hfpef (group 1) or hfref (group 2) or absent echocardiographic evidence of hfref or hfpef(group 3) and * sinus rhythm during invasive measurements * age ≥18 years * negative pregnancy test in women with childbearing potential * written informed consent exclusion criteria: * acute coronary syndrome * acute myocardial infarction \<6 months * planned cardiac surgery or cardiovascular intervention within 6 months following inclusion * valvular heart disease \>2° * severe comorbidities with limited life expectancy \<12 months * precapillary pulmonary hypertension * participation in another trial
elder-friendly approaches to the surgical environment (ease) study

Conditions: General Surgery

Summary: the aim of this study is to examine the impact implementing an elder-friendly surgical unit has on post-operative complications, mortality and quality of life for patients ≥ 65 years old who have undergone emergency surgical care.

the investigators hypothesize that the elder-friendly surgical unit will reduce in-hospital complications and mortality in a cost-effective manner, for this at risk population. specific elder-friendly interventions include: 1. locate all elderly surgical patients on one nursing unit 2. interdisciplinary team-based care 3. elder-friendly evidence-informed practices including: comfort rounds with early mobilization, delirium prevention/management, optimal nutrition and prevention of post-operative complications 4. early and interdisciplinary discharge management this is a prospective, before-after study with a concurrent control group. four senior patient groups will be followed:

Eligibility criteria:
inclusion criteria: * all patients \> 65 years old admitted for acute care and emergency surgery * received acute abdominal surgery exclusion criteria: * elective general surgery cases * nursing home resident requiring full nursing care \[dependency in 3 or more activities of daily living \] * palliative surgery \[surgery with the primary intention of improving quality of life or relieving symptoms caused by advancing non-curative disease\] * multi-system trauma * patients from out of province or transferred from another inpatient service or hospital

Keywords: senior elderly acute care emergency surgery
vision screening study for college students at nankai university

Conditions: Myoma

Summary: the prevalence of myopia among high school students in china is as high as 80%-90%. for college students with longer years of education, the majority of myopia and the factors influencing the prevalence of high myopia should be better understood for timely prevention and treatment. this study aims to investigate the prevalence of myopia and education-related influencing factors among college students at nankai university.


Eligibility criteria:
inclusion criteria: * all 1st year students exclusion criteria: * no eye diseases such as cataracts, glaucoma,keratoconus, etc. * no psychiatric disorders * astigmatism ≤ -6.00d